Studies and Researches

a) Understanding how it works;
b) Safety of the medicine.

Tasks were distributed in several centers of researches, although, naturally most of them are close to the headquarters of the company management, in Paraná. It was demonstrated that the medicine Canova doesn't have DL 50, nor genotoxicity or mutagenicity. These researches demonstrated the safety of the medicine. Researches were also initiated to explain how the medicine works and it was noticed that the main action is in a cell of the immunological system called macrophage. These cells are found in the whole human body (skins, guts viscera, blood vessels, lungs, woven of completion) and they are defense cells. It was observed that the homeopathic medicine Canova acts on the macrophages, inducing the changing of the resting state in which they are into an activated cell. Their metabolism becomes more intense, they get bigger, so then they also activate other cells of the immune system, or even functionally substituting them when they are absent, explaining this way, the patients' clinical improvement.

The researches at Federal Universities of Paraná and of Pará, demonstrated the absence of DL 50 and of genotoxicity and mutagenicity. The studies in several centers of patients care, with follow-up of clinical evaluation, laboratorial and measurements of quality of life, confirm these discoveries of the mentioned Universities, guaranteeing that, besides effective, the homeopathic medicine Canova is safe for human consumption.

The studies conducted by Professor Rommel Burbano, from the Federal University of Pará, published in Genetics Molecular and Research; 2(2): 223-228; (2003), demonstrate that the homeopathic medicine Canova doesn't have genotoxic nor mutagenic effect, which means that it is not poisonous to the genetic material, nor causes alterations in the chromosomas of the organism.

The studies performed at the Hospital of Clinics of the Federal University of Paraná, showed the hepatic protective action of the homeopathic medicine Canova on the patients that underwent the treatment with concomitant use of antiretroviral and medicine Canova. Such results, also proved in the clinical studies performed at several places of the country and overseas, strongly suggest that the homeopathic medicine Canova should be prescribed in conjunction with antiretroviral therapy.

The use of Canova medicine in conjunction with chemotherapy takes to a significant decrease of the noxious effect of those treatments, as nauseas, vomits, hair fall and so on. The medicine Canova contributes to a better adherence to the conventional therapeutic processes, such as chemotherapy or radiotherapy.

In HIV+/AIDS patients, many times a therapeutic failure happens. This failure is the consequence either viral persistency and/or mutagenicity. In spite of its efficacy, this kind of therapeutic agents shows many adverse effects, which contributes to a lack of compliance and refusal of treatment by some.

The target of the international scientist community with respect to chronic diseases consists in primary prevention, symptom relief, reconstitution of the immune system and improvement of quality of life.

In this context, national and International authorities focused attention to the medicine Canova® , which renders in several laboratory and field research performed by several institutions and professionals on the Health field since 1998.

The number of patients with cancer is increasing all over the world. Out of 9 million estimated new cases, more than the half are in developing countries and most of these patients have advanced disease when in the moment of the diagnosis.

For them — considered out of therapeutic possibility (OTP) —, the only real option of treatment is the relief of pain and the palliative cares.The OTP patients for cancer are a great problem of human and social order, in which the professional that treats the disease is confronted with a dramatic Picture of suffering and with enormous difficulty to alleviate it.

Inserted in the search of new treatment ways that make possible to increase the dignity conditions in the continuation of the oncologic disease, the study evaluated, in the clinical field, the therapeutic answer obtained with the use of Immunomodulator Canova® in oncologic patients and OTP.

The study evidenced in the clinical field Immunomodulator Canova therapeutic effectiveness in oncologic patients and Out of Therapeutic Possibilities.

The medicine showed to be a weapon of quite useful use in the institution of the palliative cares, for its actions, observed in this study, in relation to the significant improvement of the general health conditions, gaining of weight, reduction of nauseas and vomits, decrease of asthenia and increase of the patients’ willingness due to the new vitality observed from the moment that the patients themselves noticed their clinical improvement, besides the adverse effects have not been evidenced.

CABRAL, MP; SOFFRITTI, EM; NADER, JR.